Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 5/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568807 | 0.87 | IGF1R (0.45) | TBK1PDPK1MARK3MARK4STK17A | |
| SCHEMBL1937577 | 0.78 | SYK (0.50) | TBK1PDPK1MARK3MARK4STK17A | |
| SCHEMBL3566465 | 0.78 | PTK2 (0.57) | TBK1PDPK1MARK3STK17AIGF1R | |
| SCHEMBL3566625 | 0.77 | GRM4 (0.43) | TBK1PDPK1MARK3MARK4STK17A | |
| SCHEMBL1937543 | 0.77 | SYK (0.50) | TBK1PDPK1IGF1RSYKAURKA | |
| SCHEMBL13313535 | 0.74 | IGF1R (0.48) | TBK1PDPK1MARK3MARK4STK17A | |
| SCHEMBL3569508 | 0.73 | TBK1 (0.54) | TBK1MARK3MARK4STK17AIGF1R | |
| SCHEMBL12234971 | 0.72 | TBK1 (0.57) | TBK1IGF1RSYKAURKAAURKB | |
| SCHEMBL12235690 | 0.71 | IGF1R (0.56) | TBK1IGF1RSYKAURKAAURKB | |
| SCHEMBL12235693 | 0.71 | TBK1 (0.56) | TBK1IGF1RSYKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | TBK1 3976/4885PDPK1 2927/4885MARK3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.